Lifebit

Lifebit

Biotechnology Research

London, England 25,802 followers

Revolutionising genomics & bioinformatics: unified research over distributed big data powered by AI.

About us

At Lifebit, we're pushing forward the frontiers of health and knowledge by democratising access to omics data. We enable all researchers, whether novice or advanced, to run complex analyses and generate meaningful insights fast. Lifebit CloudOS is the world’s first federated genomics platform for unified and secure research over distributed big data - wherever data resides. From top tier pharmaceutical organisations to global research institutes to genetics companies and more, Lifebit CloudOS leads the way with our best-in-class UX/UI, seamless integration to open-source tools, marketplace of proprietary ones, powerful cohort browser, and advanced AI functionality. At Lifebit, we are open source pioneers, innovators redefining our industry. Our driving mission - to revolutionise bioinformatics and biomedical data analysis forever. We are growing fast and looking for more superstars to join our team.

Website
https://lifebit.ai
Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
London, England
Type
Privately Held
Founded
2017
Specialties
Software, Data Analysis, Genomics, High Performance Computing (HPC), Cloud Computing, Machine Learning, Bioinformatics, BigData, AI, Biobank, Pharmaceutical, Precision Medicine, and Drug Discovery

Products

Locations

Employees at Lifebit

Updates

  • View organization page for Lifebit, graphic

    25,802 followers

    🔬 The latest report from the Public Policy Projects' team calls for significant reforms in approaches to genomic testing in cancer care, highlighting key challenges and solutions. By addressing process and capacity issues, enhancing pathology lab resources, creating a centralised clinical trials database and increasing clinician education and awareness, the report aims to improve patient outcomes and ensure equitable access to genomic testing across the UK. 💊 Despite advancements, disparities in access remain, underscoring the need for a cultural shift in genomic medicine. You can find the full report below 👇

    View organization page for Public Policy Projects, graphic

    5,740 followers

    🚀 New Report* Launch: Transforming Genomic Testing in Cancer Care We are excited to announce the launch of our latest report, “𝐈𝐦𝐩𝐫𝐨𝐯𝐢𝐧𝐠 𝐀𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐆𝐞𝐧𝐨𝐦𝐢𝐜 𝐓𝐞𝐬𝐭𝐢𝐧𝐠 𝐚𝐧𝐝 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐟𝐨𝐫 𝐂𝐚𝐧𝐜𝐞𝐫: 𝐁𝐨𝐨𝐬𝐭𝐢𝐧𝐠 𝐎𝐮𝐭𝐜𝐨𝐦𝐞𝐬 𝐚𝐧𝐝 𝐑𝐞𝐝𝐮𝐜𝐢𝐧𝐠 𝐈𝐧𝐞𝐪𝐮𝐚𝐥𝐢𝐭𝐢𝐞𝐬." This comprehensive study by PPP calls for a significant overhaul in the NHS's approach to genomic testing in cancer care.    🔬 Key Findings:  - Process & Capacity Issues: Onerous processes and lack of understanding by clinicians are major barriers.  - Pathology Lab Resources: Increased capacity and better technology implementation are crucial.  - Centralised Clinical Trials Database: A unified system for clinical trials is needed to enhance access and scientific discovery.  - Education & Awareness: Clinicians need better education and support to advocate for genomic testing. 📉 Despite advancements, there are still variations in access to genomic testing across the UK. Many clinicians are not fully aware of the benefits, highlighting the need for a robust education programme. 💬 Dr. Tony Patrikios, Executive Medical Director at Amgen UK, comments: “Rapid and easy access to genomic testing in cancer is crucial for delivering personalised, effective, and efficient healthcare, improving outcomes, and advancing our understanding and treatment of cancer. Equally important is ensuring that access to such testing is equitable for all patients." Join us in supporting the call for a culture shift in genomic medicine within the NHS. Together, we can make genomic testing as routine and straightforward as a blood test, ensuring every patient benefits from the latest advancements in cancer care. Read the full report here: https://lnkd.in/dUzQqePM *Amgen have provided sponsorship to support the delivery of the PPP Cancer Care Programme. PPP retains editorial control across all policy programmes. #GenomicTesting #CancerCare #HealthcareInnovation #CancerResearch  Rachel Millar

    • No alternative text description for this image
  • View organization page for Lifebit, graphic

    25,802 followers

    We are pleased to introduce the Lifebit Clinical Portal v2 - our end-to-end solution to enable clinicians to enhance patient care through improved data management, integrated EHR and genomic data and AI to deliver more accurate diagnostics, and personalized treatments for patients. The key features of our Clinical Portal include: ✅ Robust patient management: Integrate patient histories, treatment plans and ongoing care information. ✅ Automated recruitment & consent management: Streamline and track patient consents quickly & securely, facilitating faster approvals for critical tests and treatments. ✅ Criteria-based notifications: Deploy automated alerts that notify healthcare teams immediately when patients meet predetermined diagnostic or therapeutic criteria. ✅ Seamless clinical note integration: Directly integrate and synchronize clinical notes within patients’ EHR systems, maintaining a single, consistent, and comprehensive patient health record. ✅ Pharmacogenomic reporting: Produce individual participant pharmacogenomic reports to guide clinicians for treatment and dosage recommendations. ✅ Comprehensive genomic data analysis: Scrutinize patient-specific genomic data to detect significant genetic variants that could inform therapeutic strategies. ✅ Dynamic variant filtering and therapy recommendations: Deliver precise therapy recommendations, streamlining the clinical decision-making process. The Lifebit Clinical Portal integrates AI & advanced software capabilities with genomic and health data to streamline patient workflows and ensure more efficient & accurate data management. We are supporting healthcare providers across the world to increase diagnostic accuracy and improve individualized patient care, setting new benchmarks in precision medicine. You can learn more about how our platform meets the complex needs of modern medical institutions in our latest blog: https://bit.ly/3zvkfAd #PrecisionMedicine #Genomics #AI #PatientData #Lifebit

    • No alternative text description for this image
  • View organization page for Lifebit, graphic

    25,802 followers

    The drug development process faces significant challenges, with nearly 86% of all trials failing to meet enrollment goals. 🔬 Check out our newest blog for an in-depth look at the crucial steps in patient recruitment and enrollment, challenges, and cutting-edge solutions. Find out how AI, machine learning and digital tools can enhance clinical trial processes, lower expenses and speed up drug approvals: https://bit.ly/3L8uQ6r #ClinicalTrials #PatientEngagement #Diversity #HealthTech #Lifebit

    • No alternative text description for this image
  • View organization page for Lifebit, graphic

    25,802 followers

    🚀 Lifebit will be exhibiting at the Genomics England Research Summit 2024 on Tuesday July 9th! The event will be a fantastic opportunity to delve into the latest advancements in genomics research and collaborate with some of the leading experts in the field. Through our poster presentations, you can learn our methods for identifying undiagnosed patients using the most recent data from the 100,000 Genomes Project and how Lifebit utilises our CloudOS Platform to lead mtDNA-focused genotype-phenotype approaches for diagnosing rare diseases. We look forward to connecting with you and sharing our insights. See you there! #GERS2024 #RareDisease #Genomics

    • No alternative text description for this image
  • View organization page for Lifebit, graphic

    25,802 followers

    We are proud to share highlights from the Marie Claire Power Trip 2024, where our CEO, Dr. Maria C. Dunford, participated in an insightful discussion on AI and the future of entrepreneurship. Moderated by Lina Tsaltampasi, President of SEGE - Greek Association of Women Entrepreneurs , Maria joined industry leaders Alessandra Delfini, General Director at L'Oréal Hellas and Athina Pachatouridis, Strategic Sales Leader for Central and Eastern Europe, Amazon Web Services (AWS) Coordination, to discuss how AI integration with human expertise can drive innovation and create new opportunities, especially for women entrepreneurs. Dive into the details in our latest blog 🚀 https://bit.ly/4bEhN7X #AI #WomenInTech #Sustainability #Lifebit

    • No alternative text description for this image
  • View organization page for Lifebit, graphic

    25,802 followers

    🧠 We are proud to unveil our new white paper titled "Designing Clinical Trials for Optimal Success", offering innovative strategies and best practices to enhance the reliability and impact of clinical research. In this white paper, you will learn about: - Ensuring robust study design with RCTs, observational studies, and adaptive trial designs. - Selecting relevant and diverse patient populations to ensure generalizability. - Identifying appropriate endpoints and outcome measures. - Robust statistical analysis methods, including Bayesian approaches. - The role of real-world data in complementing traditional trial designs. Stay ahead in clinical research and ensure your trials are designed for success. 📖 Access your copy now: https://bit.ly/3WaX1bz #ClinicalTrials #MedicalResearch #ClinicalResearch #WhitePaper #Lifebit

    • No alternative text description for this image
  • View organization page for Lifebit, graphic

    25,802 followers

    Find out how federated data analysis is boosting genomics research in our blog post! Genomics research is transforming personalised medicine by studying complete DNA. However, accessing relevant genomic data poses challenges due to security, privacy and data volume. The solution? Data federation. Data federation enables secure access without data movement, fostering collaboration worldwide. With billions of gigabytes generated annually, duplication and movement are costly. Federated analysis saves time and money by analysing distributed data in parallel. Researchers can combine genomic data securely, maximising discoveries. From rare diseases to COVID-19 insights, the potential is immense. For more insights: https://bit.ly/3Xnlv2a #GenomicData #Genomics #DataAnalysis #Lifebit

    • No alternative text description for this image
  • View organization page for Lifebit, graphic

    25,802 followers

    🔬 Take a deep dive into our blog post to uncover the challenges faced in drug discovery. Uncover how AI and ML are revolutionising the field, breaking down cost and time barriers to drive progress in Drug Discovery 2.0. Our blog delves into the intricate journey of drug development, where new drugs must meet stringent efficacy and safety standards in extensive clinical trials. Did you know that, on average, it takes 10 to 15 years and costs approximately $2 billion to bring a drug to market? These figures highlight the complexities and financial burdens inherent in the process. But there's hope on the horizon with Drug Discovery 2.0 🚀 Advances in AI and ML are set to transform drug development by analysing vast biomedical datasets, accelerating the identification of novel compounds and targets. Gain deeper insights into the challenges and opportunities of drug discovery now: https://hubs.li/Q02CcjWQ0 #DrugDiscovery #AIinHealthcare #Lifebit

    • No alternative text description for this image
  • View organization page for Lifebit, graphic

    25,802 followers

    Discover how Trusted Research Environments (TREs) are revolutionising data accessibility in the UK in our blog. TREs allow secure, remote access to sensitive health data, empowering researchers while protecting patient privacy. Explore use cases and see how TREs facilitate innovative research. Learn more about the principles, regulation and implementation of TREs in the UK, and how they are driving forward the future of health data science: https://bit.ly/45CkFR9 #TRE #DataSecurity #HealthData #Lifebit

    • No alternative text description for this image

Similar pages

Browse jobs

Funding